News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No news articles were provided in the past hour; no new headlines to summarize.
  • No market-moving developments appeared in the supplied articles during this hour.
  • Real-time market data may still show activity not captured by the empty article set.
  • Please provide articles or enable a live news feed to receive populated hourly snapshots.
  • No policy, earnings, or geopolitical headlines were present in the provided articles this hour.

Latest Articles

Evommune Shares Collapse After EVO756 Phase 2b Top-Line Readout Disappoints

Evommune Shares Collapse After EVO756 Phase 2b Top-Line Readout Disappoints

Evommune Inc. shares tumbled 27.4% in after-hours trading to $9.50 after the company released top-line Phase 2b results for EVO756 in moderate-to-severe atopic dermatitis, a milestone it had highlighted for September 2026. The decline compounds pressure from an earlier Phase 2b failure in chronic spontaneous urticaria and has driven the stock below…

Evommune Shares Plunge After EVO756 Fails to Hit Trial Goals; Company Reprioritizes Atopic Dermatitis Program

Evommune Shares Plunge After EVO756 Fails to Hit Trial Goals; Company Reprioritizes Atopic Dermatitis Program

Evommune Inc reported that its oral candidate EVO756 did not achieve the primary endpoint or secondary endpoints in a randomized, double-blind, placebo-controlled Phase 2b trial in adults with moderate-to-severe atopic dermatitis, triggering a 27% drop in after-hours trading. The company will not pursue EVO756 for atopic dermatitis and will instead…

Buy THLLY on the Oversold Dip - Play Europe's Defense & Space Rebound

Buy THLLY on the Oversold Dip - Play Europe's Defense & Space Rebound

THLLY (THALES UNSP ADR) is trading at $53.78 on the OTC market, showing clear technical oversold signals and a pick-up in short interest that could accelerate a rebound. Industry fundamentals - from air traffic control modernization to 5G NTN and public safety spending - are favorable, and a targeted long entry with tight risk control offers an asy…

Colombian equities tick higher as COLCAP posts fresh record close

Colombian equities tick higher as COLCAP posts fresh record close

Colombia's main stock benchmark closed modestly higher, with the COLCAP index reaching a new record. Strength in Industrials, Services and Agriculture supported the advance, led by a sharp jump in Etb. Several financial and investment names finished lower, and select commodities including coffee, cocoa and gold declined.

El Pollo Loco: Taco Bell-ification Driving Scalable Traffic and Margins

El Pollo Loco: Taco Bell-ification Driving Scalable Traffic and Margins

El Pollo Loco is executing a Taco Bell-style playbook: national promotions, menu innovation and a faster unit roll-out to convert a regional favorite into a scalable chain. Fundamentals and margins are improving, valuation looks reasonable at a $462M market cap, and an imminent marketing catalyst gives a clear entry opportunity. Trade idea below wi…

Moscow shares close higher as oil and telecoms lift MOEX - Index up 0.46%

Moscow shares close higher as oil and telecoms lift MOEX - Index up 0.46%

Russian equities finished the session higher, with the MOEX Russia Index up 0.46% as gains in the Oil & Gas, Manufacturing and Telecoms sectors supported the market. Notable winners included TATNEFT ordinary and preferred shares and Surgutneftegas, while Magnitogorskiy Metallurgicheskiy Kombinat and Magnit lagged. Market breadth favored decliners, …

Blackstone Initiates Sale Process for ZO Skin Health, Sources Say

Blackstone Initiates Sale Process for ZO Skin Health, Sources Say

Blackstone has begun exploring a sale of medical-grade skincare brand ZO Skin Health, with the company’s value in any potential transaction estimated at about $2 billion, according to people familiar with the matter. The firm has engaged Citigroup and Raymond James to advise on the early-stage process; representatives for the parties did not provid…

Gauzy Announces Reverse Share Split

Gauzy Announces Reverse Share Split

Gauzy Ltd., a global leader in vision and light control technologies, announces a 1-for-20 reverse share split effective September 10, 2026, to increase per share trading price and comply with Nasdaq's minimum bid price requirement. The split will reduce the number of outstanding shares and adjust related equity instruments without affecting shareh…